At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
In Brief
A Phase 3 clinical trial evaluating Asparaginase, Asparaginase Erwinia chrysanthemi, and 6 other interventions for Acute Myeloid Leukemia and 4 related conditions. Active but no longer recruiting, targeting 280 participants across 191 sites in 6 countries.
Detailed Summary
This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Response-based chemotherapy separates patients into different risk groups and treats them according to how they respond to the first course of treatment (Induction I). Response-based treatment may be effective in treating acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome while reducing the side effects.
Study Details
Timeline
Interventions
Given IM or IV
Given IM or IV
Given IT and IV
Given IV
Given IV
Correlative studies
Given IV
Given PO